Equities analysts expect Catalent, Inc. (NYSE:CTLT) to post $826.49 million in sales for the current fiscal quarter, according to Zacks Investment Research. Six analysts have made estimates for Catalent's earnings, with the highest sales estimate coming in at $873.60 million and the lowest estimate coming in at $785.13 million. Catalent posted sales of $664.70 million in the same quarter last year, which suggests a positive year-over-year growth rate of 24.3%. The business is expected to report its next quarterly earnings results before the market opens on Tuesday, November 3rd.
According to Zacks, analysts expect that Catalent will report full-year sales of $3.56 billion for the current year, with estimates ranging from $3.50 billion to $3.72 billion. For the next fiscal year, analysts forecast that the company will report sales of $3.89 billion, with estimates ranging from $3.78 billion to $4.09 billion. Zacks' sales calculations are an average based on a survey of sell-side research firms that that provide coverage for Catalent.
Catalent (NYSE:CTLT) last announced its earnings results on Monday, August 31st. The company reported $0.90 EPS for the quarter, beating analysts' consensus estimates of $0.79 by $0.11. Catalent had a return on equity of 14.88% and a net margin of 7.13%. The business had revenue of $947.60 million during the quarter, compared to analysts' expectations of $943.62 million. During the same quarter in the prior year, the firm earned $0.70 earnings per share. The business's revenue was up 30.6% compared to the same quarter last year.
A number of brokerages have commented on CTLT. Royal Bank of Canada increased their target price on Catalent from $94.00 to $98.00 in a report on Tuesday, September 1st. Argus increased their price target on Catalent from $100.00 to $110.00 in a report on Thursday, September 24th. Deutsche Bank Aktiengesellschaft increased their price target on Catalent from $62.00 to $91.00 and gave the company a "hold" rating in a report on Friday, September 4th. Robert W. Baird increased their price target on Catalent from $90.00 to $100.00 and gave the company an "outperform" rating in a report on Tuesday, September 1st. They noted that the move was a valuation call. Finally, Zacks Investment Research raised Catalent from a "hold" rating to a "buy" rating and set a $97.00 price target for the company in a report on Monday, August 17th. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. Catalent has an average rating of "Buy" and a consensus price target of $96.78.
Shares of Catalent stock opened at $92.40 on Friday. The business has a 50 day simple moving average of $86.75 and a two-hundred day simple moving average of $76.80. Catalent has a 12 month low of $31.04 and a 12 month high of $96.38. The stock has a market capitalization of $15.20 billion, a P/E ratio of 83.24, a PEG ratio of 2.64 and a beta of 1.58. The company has a debt-to-equity ratio of 1.02, a current ratio of 2.57 and a quick ratio of 2.20.
In other news, Director Gregory T. Lucier sold 24,000 shares of the firm's stock in a transaction on Thursday, July 30th. The stock was sold at an average price of $90.09, for a total transaction of $2,162,160.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO John R. Chiminski sold 182,231 shares of the firm's stock in a transaction on Friday, October 2nd. The stock was sold at an average price of $86.01, for a total value of $15,673,688.31. The disclosure for this sale can be found here. Insiders sold 233,433 shares of company stock valued at $20,304,879 over the last quarter. 1.00% of the stock is currently owned by company insiders.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Cambridge Investment Research Advisors Inc. boosted its position in shares of Catalent by 2.5% during the second quarter. Cambridge Investment Research Advisors Inc. now owns 4,919 shares of the company's stock worth $361,000 after buying an additional 122 shares during the period. Integrated Investment Consultants LLC boosted its position in shares of Catalent by 3.3% during the first quarter. Integrated Investment Consultants LLC now owns 5,203 shares of the company's stock worth $270,000 after buying an additional 167 shares during the period. Signaturefd LLC raised its stake in shares of Catalent by 133.3% in the second quarter. Signaturefd LLC now owns 385 shares of the company's stock valued at $28,000 after acquiring an additional 220 shares in the last quarter. Shilanski & Associates Inc. raised its stake in shares of Catalent by 2.1% in the second quarter. Shilanski & Associates Inc. now owns 13,098 shares of the company's stock valued at $960,000 after acquiring an additional 273 shares in the last quarter. Finally, Pendal Group Ltd raised its stake in shares of Catalent by 14.5% in the second quarter. Pendal Group Ltd now owns 2,772 shares of the company's stock valued at $203,000 after acquiring an additional 351 shares in the last quarter.
Catalent Company Profile
Catalent, Inc, together with its subsidiaries, provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services.
Further Reading: Outstanding Shares, Buying and Selling Stocks
Get a free copy of the Zacks research report on Catalent (CTLT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
7 Virus-Resistant Retail Stocks to Own Now
The U.S. economy contracted by 5% in the first quarter. That was slightly larger than the 4.8 decline that was previously forecast. On the same day that GDP was released, we also learned that the ranks of those filing for unemployment claims exceeded 40 million.
But as sobering as those numbers are, they’re not completely surprising. The U.S. economy was effectively shut down as citizens did their part to slow the spread of the novel coronavirus. But the cost of those efforts is just being measured.
And one of those measurements comes in the all-important Consumer Confidence Index. The index ticked up slightly in May to 86.6. While this number is about 30% lower than where the index sat In February, it’s significantly higher than where it sat at the trough of the financial crisis and subsequent recession.
And a big reason for that is that while the brick-and-mortar economy shut down, the digital economy helped give the economy a pulse.
Consumption is a key part of our economy. That’s why consumer confidence makes up 70% of the U.S. economy. And one of the key ways that consumers express that confidence or lack thereof, is in the retail sector.
For the last few years, the story of retail has been about which retailers were going to be able to successfully compete in the e-commerce space that is still owned by Amazon (NASDAQ:AMZN). Sadly, we’re discovering that some companies, like J.C. Penney, were late to adapt in a meaningful way. But that isn’t the case for all retailers.
In this special presentation, we are identifying 7 retail stocks that have done well through this turbulent time and should use that as a springboard to continued growth.
View the "7 Virus-Resistant Retail Stocks to Own Now".